Human Phenotyping Core
Human Phenotyping Core
批准号:
10478211
负责人:
Joel Marvin Guthridge
金额:
$36.85万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-09-07 至 2023-08-31
关键词:
AddressAutoantibodiesAutoimmune DiseasesBiological AssayBiological MarkersBlood CellsCaringCellsCellular Indexing of Transcriptomes and Epitopes by SequencingCharacteristicsClinicalCompetenceComplexConsultationsDataData AnalysesData SetDatabasesDevelopmentDiagnosticDiseaseEffectivenessEnsureEpigenetic ProcessEquipmentExperimental DesignsFlow CytometryFoundationsFreezingFundingFutureGenerationsGeneticGenetic PolymorphismGenomic DNAGenomicsGenotypeHumanHuman Herpesvirus 4Human ResourcesImmuneImmunologicsImmunophenotypingIndividualInflammatoryInvestigationKnowledgeMeasuresMediator of activation proteinMethodologyMethodsMolecularMolecular ProfilingOklahomaPathogenesisPathway interactionsPatientsPhenotypePlasmaPopulationPreparationProcessProteomicsQuality ControlReproducibilityResearchResearch PersonnelResourcesRheumatismSamplingSerumServicesSiteSpecimenStatistical ModelsSystemTechnical ExpertiseTechnologyTherapeuticTimeTransformed Cell LineVariantbasebiobankchemokineclinical centerclinical phenotypeclinically relevantcomputerized data processingcytokinedata qualitydesignexperienceexperimental studyhuman diseaseimmune functionmolecular phenotypenovelnovel strategiesphenotypic dataprecision medicineprognostic toolprogramsresponsesingle-cell RNA sequencingsuccesstranscriptometranscriptomics
中文摘要
人类表型核心项目总结
询问免疫和炎症系统的新方法的迅速发展
对这些方法的技术和概念专业知识的需求日益增长。《人类》
表型核心是为了支持俄克拉荷马州风湿病资源中的这些活动而创建的
岩心中心(ORDRCC)。以解决最具科学意义和临床重要性的
问题,我们的ORDRCC调查人员需要使用尖端方法,如scRNA-Seq/Cite-
SEQ、芯片细胞术和CyTOF,以执行深入的实验并生成高质量、可重复性的
数据。人类表型核心将允许我们的研究人员提出关于分子的新问题
风湿性疾病的表型。除了为ORDRCC调查人员提供高内容
生物分子表型服务,人类表型核心与临床
特征和生物资源库核心(CCBC)将提供对包含以前
收集样本可用的临床受试者的遗传、蛋白质组和生物分子表型
来自CCBC。人类表型核心、CCBC和我们的数据库的紧密集成将使
研究人员高效地采集表型样本,并将分子和细胞表型与临床联系起来
特征,以选择更多同质性的患者进行假设驱动的研究,并帮助提供
风湿病护理中精准医学所需的基础知识。
通过整合完整表征分子或蛋白质的一系列技术
将细胞表型整合为一个单位,人类表型核心(HPC)将简化服务,以帮助
ORDRCC调查人员高效的规划、设计、执行和数据分析
个别项目。HPC将提供使用临床标本进行研究的经验,
在广泛的分子和生物分析方面的技术专长,从而获得设备和资源
采用前沿方法解决研究问题,对数据进行质量控制评估
适用于表型/临床关联的高端统计建模的收集和数据处理。
具体目标1:协助ORDRCC调查人员、JCI和学者浏览项目的各个阶段
翻译和机械研究的开发、实验设计、资源规划和执行
通过核心管理和个人协商。
具体目标2:提供先进的分子表型技术和经验
高效执行高级实验数据计划的技术人员。
具体目标3:建立流程以确保数据质量控制、原始数据处理和准备
用于更广泛的分析和统计建模的数据集。
具体目标4:评估、评估和实施新的前沿分子表型技术。
英文摘要
Human Phenotyping Core Project Summary
The rapid development of new approaches to interrogate the immune and inflammatory systems comes
with a growing demand for both technical and conceptual expertise in these methodologies. The Human
Phenotyping Core was created to support these activities within the Oklahoma Rheumatic Disease Resources
Cores Center (ORDRCC). To address the most broadly scientifically interesting and clinically important
questions, our ORDRCC Investigators need access to cutting-edge approaches, such as scRNA-Seq/CITE-
Seq, ChipCytometry, and CyTOF to perform incisive experiments and to generate high-quality, reproducible
data. The Human Phenotyping Core will allow our investigators to ask novel questions regarding the molecular
phenotypes of rheumatic diseases. In addition to providing ORDRCC investigators with high-content
biomolecular phenotyping services, the Human Phenotyping Core in conjunction with the Clinical
Characterization and Biorepository Core (CCBC) will provide access to datasets containing previously
collected genetic, proteomic, and biomolecular phenotypes of clinical subjects whose samples are available
from the CCBC. The tight integration of the Human Phenotyping Core, CCBC and our databases will enable
investigators to efficiently phenotype samples and correlate molecular and cellular phenotypes with clinical
characteristics, to select more homogeneous patients for hypothesis-driven investigation and help provide the
foundational knowledge needed for precision medicine in rheumatic disease care.
By consolidating a range of technologies required for the complete characterization of molecular or
cellular phenotypes into a single unit, the Human Phenotyping Core (HPC) will streamline services to help
ORDRCC investigators in the efficient planning, design, execution and data analysis required for their
individual projects. The HPC will provide experience in performing research using clinical specimens,
technical expertise in a wide range of molecular and bioassays, access to equipment and resources thus
enabling cutting-edge approaches to address research questions, quality control assessment of the data
collected and data processing suitable for higher end statistical modeling of phenotype/clinical associations.
SPECIFIC AIM 1: Assist ORDRCC Investigators, JCIs and Scholars to navigate the stages of project
development, experimental design, resource planning and execution of translational and mechanistic studies
through Core Management and individual consultations.
SPECIFIC AIM 2: Provide access to advanced molecular phenotyping technologies and experienced
technical personnel for efficient execution of advanced experimental data plans.
SPECIFIC AIM 3: Establish processes to ensure data quality control, processing of raw data, and preparation
of data sets for more extensive analysis and statistical modeling.
SPECIFIC AIM 4: Evaluate, assess and implement new cutting-edge technologies for molecular phenotyping.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mechanisms of New-Onset Autoimmunity/Longitudinal Immune Systems Analysis (MONA-LISA)
-
批准号:10655219
-
项目类别:
-
资助金额:$129.11万
-
财政年份:2023
-
负责人:Joel Marvin Guthridge
-
依托单位:
Accelerating Medicines Partnership-Autoimmune and Immunologic Disease Tissue Research Core Admin Supplement: Preclinical Studies in Sjogren's
-
批准号:10834635
-
项目类别:
-
资助金额:$146.04万
-
财政年份:2022
-
负责人:Joel Marvin Guthridge
-
依托单位:
Accelerating Medicines Partnership-Autoimmune and Immunologic Disease Tissue Research Core
-
批准号:10687729
-
项目类别:
-
资助金额:$14.13万
-
财政年份:2022
-
负责人:Joel Marvin Guthridge
-
依托单位:
Accelerating Medicines Partnership-Autoimmune and Immunologic Disease Tissue Research Core
-
批准号:10452026
-
项目类别:
-
资助金额:$505.0万
-
财政年份:2022
-
负责人:Joel Marvin Guthridge
-
依托单位:
Accelerating Medicines Partnership-Autoimmune and Immunologic Disease Tissue Research Core
-
批准号:10596177
-
项目类别:
-
资助金额:$728.96万
-
财政年份:2022
-
负责人:Joel Marvin Guthridge
-
依托单位:
Human Phenotyping Core
-
批准号:10016171
-
项目类别:
-
资助金额:$36.85万
-
财政年份:2018
-
负责人:Joel Marvin Guthridge
-
依托单位:
Human Phenotyping Core
-
批准号:10704390
-
项目类别:
-
资助金额:$34.1万
-
财政年份:2018
-
负责人:Joel Marvin Guthridge
-
依托单位:
Ikaros family genes and lupus susceptibility across ethnically diverse populations
-
批准号:9770772
-
项目类别:
-
资助金额:$82.71万
-
财政年份:2018
-
负责人:Joel Marvin Guthridge
-
依托单位:
Ikaros family genes and lupus susceptibility across ethnically diverse populations
-
批准号:10238826
-
项目类别:
-
资助金额:$78.17万
-
财政年份:2018
-
负责人:Joel Marvin Guthridge
-
依托单位:
Human Phenotyping Core
-
批准号:10251965
-
项目类别:
-
资助金额:$36.85万
-
财政年份:2018
-
负责人:Joel Marvin Guthridge
-
依托单位:
CORE E: BIOREPOSITORY CORE
-
批准号:8359799
-
项目类别:
-
资助金额:$3.88万
-
财政年份:2011
-
负责人:Joel Marvin Guthridge
-
依托单位:
CORE F: SERUM ANALYTE AND BIOMARKER CORE
-
批准号:8364935
-
项目类别:
-
资助金额:$20.73万
-
财政年份:2011
-
负责人:Joel Marvin Guthridge
-
依托单位:
OK COBRE: GENETICS OF B LYMPHOCYTE SIGNALING IN LUPUS
-
批准号:7960574
-
项目类别:
-
资助金额:$12.59万
-
财政年份:2009
-
负责人:Joel Marvin Guthridge
-
依托单位:
PEPTIDE SYNTHESIS CORE
-
批准号:7959377
-
项目类别:
-
资助金额:$7.23万
-
财政年份:2009
-
负责人:Joel Marvin Guthridge
-
依托单位:
Genetic and Functional Analysis of LYN Alleles Associated with Lupus
-
批准号:7938654
-
项目类别:
-
资助金额:$7.96万
-
财政年份:2009
-
负责人:Joel Marvin Guthridge
-
依托单位:
Genetic and Functional Analysis of LYN Alleles Associated with Lupus
-
批准号:7680457
-
项目类别:
-
资助金额:$7.75万
-
财政年份:2008
-
负责人:Joel Marvin Guthridge
-
依托单位:
CORE: PEPTIDE SYNTHESIS CORE FACILITY
-
批准号:7720053
-
项目类别:
-
资助金额:$7.06万
-
财政年份:2008
-
负责人:Joel Marvin Guthridge
-
依托单位:
OK COBRE: GENETICS OF B LYMPHOCYTE SIGNALING IN LUPUS
-
批准号:7720937
-
项目类别:
-
资助金额:$13.73万
-
财政年份:2008
-
负责人:Joel Marvin Guthridge
-
依托单位:
Phenotyping Core
-
批准号:8444002
-
项目类别:
-
资助金额:$38.34万
-
财政年份:2007
-
负责人:Joel Marvin Guthridge
-
依托单位:
Phenotyping Core
-
批准号:9136767
-
项目类别:
-
资助金额:$38.34万
-
财政年份:2007
-
负责人:Joel Marvin Guthridge
-
依托单位:
海外基金